

SAGE Therapeutics Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 06-Jun-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 9

 Phase 3 Clinical..... 10

 Discovery..... 15

[Return to Table of Contents](#)

SAGE Therapeutics Inc

COMPANY OVERVIEW

Company Name	SAGE Therapeutics Inc
Parent Company Name	SAGE Therapeutics Inc
Website	http://www.sagerx.com/
Country	US
Number of Drugs in Active Development	6
Number of Inactive Drugs	4
Number of Patents as Owner	16
Number of Patents as Third Party	0
Number of Deals	4
Key Indications	Status epilepticus, Central nervous system disease, Psychiatric disorder, Epilepsy, Anesthesia, Rett syndrome, Essential tremor, Mood disorder, Neurological disease, Postnatal depression
Key Target-based Actions	GABA A receptor modulator, NMDA receptor modulator, GABA A receptor alpha-1 subunit modulator, GABA A receptor alpha-4 subunit modulator, GABA A receptor delta subunit modulator, GABA A receptor beta-2 subunit inhibitor, GABA A receptor beta-3 subunit inhibitor, GABA A receptor gamma-2 subunit inhibitor, GABA A receptor agonist, GABA A receptor alpha-1 subunit stimulator, GABA A receptor beta-2 subunit modulator, GABA A receptor beta-2 subunit stimulator, GABA A receptor beta-3 subunit modulator, GABA A receptor gamma-2 subunit modulator, GABA A receptor gamma-2 subunit stimulator, GABA B receptor agonist, GABA receptor antagonist, GABA receptor modulator, NMDA receptor agonist
Key Technologies	Small molecule therapeutic, Intravenous formulation, Oral formulation, Steroid, Infusion, Analytical method, Pharmaceutical carrier

COMPANY PROFILE

SUMMARY

SAGE Therapeutics is a pharmaceutical company, focused on developing medicines for central nervous system disorders.

FINANCIAL

In April 2015, the company priced an underwritten public offering of 2,285,714 shares of its common stock at a public offering price of \$52.50 per share. The company granted the underwriters a 30-day option to purchase up to an additional 342,857 shares of common stock. At that time, the offering was expected to close on or about April 20, 2015. Later that month, the offering was closed with 2,628,571 shares sold including the full exercise of the additional shares offered. At that time, the company raised gross proceeds of approximately \$138 million.

In April 2015, the company proposed an underwritten public offering of \$100 million of shares of its common stock. The company granted the underwriters a 30-day option to purchase up to an additional \$15 million of shares of common stock.

In December 2014, the company was added to the NASDAQ Biotechnology Index (NBI) which would become effective upon market open on December 22, 2014.

In July 2014, the company announced the pricing of its initial public offering of 5 million shares of common stock at a price of \$18 per share. The underwriters were also granted a 30-day option to buy up to an additional 0.75 shares at the same offering price to cover over-allotments, if any. The company's shares were expected to begin trading on the NASDAQ Global market on July 18, 2014, under the ticker symbol 'SAGE'. Later that month, the underwriters exercised their full option to purchase additional shares of the IPO. At that time, the company raised a capital of \$103.5 million from a total of 5.75 million shares sold and the offering was closed.

[Return to Table of Contents](#)



In March 2014, the company raised \$38 million from an oversubscribed series C financing.

In October 2013, the company raised \$20 million from a series B financing.


In October 2011, SAGE secured \$35 million in series A financing. By September 2013, the company raised \$37.8 million totally from the completion of series A financing.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	6	4	10
Psychiatric disorder	4	0	4
Injury	0	1	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Discovery	5
No Development Reported	4

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	0	0	1	0	1
Drug - Funding	1	0	0	0	1
Drug - Early Research/Development	0	0	1	0	1
Drug - Development/Commercialization License	0	0	1	0	1

[Return to Table of Contents](#)



CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neurological disease	1	8
Psychiatric disorder	0	1

Trials by Phase

Phase	Ongoing	All
Phase 3	0	1
Phase 2	0	4
Phase 1	1	1
Phase not specified	0	3

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	7	0	7
Degeneration	1	0	1
Psychiatric disorder	12	0	12
Genetic disorder	8	0	8
Neurological disease	17	0	17
Injury	8	0	8
Toxicity and intoxication	10	0	10
Otorhinolaryngological disease	6	0	6

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

SAGE-547

SAGE-547 SNAPSHOT

Drug Name	SAGE-547
Key Synonyms	
Originator Company	SAGE Therapeutics Inc
Active Companies	SAGE Therapeutics Inc
Inactive Companies	
Highest Status	Phase 3 Clinical
Active Indications	Status epilepticus;Postnatal depression;Essential tremor
Target-based Actions	GABA A receptor modulator
Other Actions	Anticonvulsant agent;Neuroprotectant
Technologies	Small molecule therapeutic;Intravenous formulation;Infusion
Last Change Date	15-May-2015

SAGE-547 DEVELOPMENT PROFILE

SUMMARY

SAGE Therapeutics is developing SAGE-547 (SGE-102, allopregnanolone), the lead from an allosteric GABA A receptor modulator program that incorporates Ligand's Captisol technology, for the potential iv treatment of status epilepticus, essential tremor and postpartum depression ,,,. In April 2015, a phase III study for super-refractory status epilepticus (SRSE) was initiated. In October 2014, the first patient was dosed in a phase IIa trial for essential tremor. In November 2014, data from a trial in pediatric patients were published. In September 2014, a phase II study was initiated in the US in patients with severe postpartum depression. In April 2015, the company planned to submit an NDA for SRSE. In March 2014, the company was seeking to outlicense its programs.

SAGE-547 DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
SAGE Therapeutics Inc	Status epilepticus	US	Phase 3 Clinical	20-Apr-2015
SAGE Therapeutics Inc	Essential tremor	US	Phase 2 Clinical	23-Oct-2014
SAGE Therapeutics Inc	Postnatal depression	US	Phase 2 Clinical	30-Sep-2014

[Return to Table of Contents](#)



SAGE-547 CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
516-54-1	3
	
Name	Type
LJPC-0712	Research Code
allopregnanolone	
allopregnan-3alpha-ol-20-one	
epiallopregnanolone	

SAGE-547 DRUG NAMES

Names	Type
SGE-102	Research Code
SAGE-547	Research Code
allopregnanolone	
allosteric GABA A receptor modulators (CNS disorders), SAGE	

SAGE-547 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Status epilepticus											
0	0	0	1	0	1	1	1	0	3	1	6
Essential tremor											
0	0	0	0	0	2	0	0	0	0	0	2

[Return to Table of Contents](#)

Postnatal depression											
0	0	0	0	0	1	0	0	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	1	0	4	1	1	0	3	1	9

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

SAGE-547 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
SAGE Therapeutics Inc	0	0	2	0	2
Ligand Pharmaceuticals Inc	1	0	0	0	1
University of California	1	0	0	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Technology - Other Proprietary	1	0	1
Drug - Early Research/Development	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
SAGE Therapeutics Inc	3	0	3

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	1
New use	1
Formulation	1

[Return to Table of Contents](#)

GABA A allosteric modulators (neuropsychiatric diseases), SAGE Therapeutics / Washington University in St. Louis

GABA A allosteric modulators (neuropsychiatric diseases), SAGE Therapeutics / Washington University in St. Louis SNAPSHOT

Drug Name	GABA A allosteric modulators (neuropsychiatric diseases), SAGE Therapeutics / Washington University in St. Louis
Key Synonyms	
Originator Company	SAGE Therapeutics Inc
Active Companies	Washington University in St Louis;SAGE Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Neurological disease;Psychiatric disorder
Target-based Actions	GABA A receptor modulator
Other Actions	Neuroprotectant
Technologies	Small molecule therapeutic
Last Change Date	26-Nov-2014

GABA A allosteric modulators (neuropsychiatric diseases), SAGE Therapeutics / Washington University in St. Louis DEVELOPMENT PROFILE

SUMMARY

SAGE Therapeutics is collaborating with Washington University in St. Louis to investigate small molecule GABAA receptor allosteric modulators, including SGE-516, using SAGE's Positive and Negative Allosteric Modulator (PANAM) platform and the University's technology, for the potential treatment of neuropsychiatric diseases, including seizures . In November 2014, preclinical data were presented.

GABA A allosteric modulators (neuropsychiatric diseases), SAGE Therapeutics / Washington University in St. Louis DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
SAGE Therapeutics Inc	Neurological disease	US	Discovery	19-Dec-2013
SAGE Therapeutics Inc	Psychiatric disorder	US	Discovery	19-Dec-2013
Washington University in St Louis	Neurological disease	US	Discovery	19-Dec-2013
Washington University in St Louis	Psychiatric disorder	US	Discovery	19-Dec-2013

[Return to Table of Contents](#)


GABA A allosteric modulators (neuropsychiatric diseases), SAGE Therapeutics / Washington University in St. Louis DRUG NAMES

Names	Type
SGE-516	Research Code
GABA A allosteric modulators (neuropsychiatric diseases), SAGE Therapeutics / Washington University in St. Louis	

GABA A allosteric modulators (neuropsychiatric diseases), SAGE Therapeutics / Washington University in St. Louis DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Washington University in St Louis	1	0	0	0	1
SAGE Therapeutics Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

SAGE-689

SAGE-689 SNAPSHOT

Drug Name	SAGE-689
Key Synonyms	
Originator Company	SAGE Therapeutics Inc
Active Companies	SAGE Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Status epilepticus;Anesthesia
Target-based Actions	
Other Actions	Anesthetic;Anticonvulsant agent;Unspecified drug target
Technologies	Small molecule therapeutic;Intravenous formulation
Last Change Date	02-Mar-2015

SAGE-689 DEVELOPMENT PROFILE

SUMMARY

SAGE Therapeutics is investigating SAGE-689 (SGE-689; SGE-202), for the potential iv use as an anesthetic and for the potential treatment of status epilepticus,. In April 2013, the drug was listed as being in preclinical development as an anesthetic ; in March 2014, the drug was listed as being in preclinical development for both neuroanesthesia and status epilepticus. In February 2015, a phase I trial was expected to be initiated by that year-end. In March 2014, the company was seeking to outlicense its programs.

SAGE-689 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
SAGE Therapeutics Inc	Anesthesia	US	Discovery	12-Apr-2013
SAGE Therapeutics Inc	Status epilepticus	US	Discovery	27-Mar-2014

[Return to Table of Contents](#)



SAGE-689 DRUG NAMES

Names	Type
SGE-202	Research Code
SGE-689	Research Code
SAGE-689	Research Code
anesthetic (intravenous, anesthesia), SAGE Therapeutics	

allosteric NMDA receptor modulators (CNS disorders), SAGE

allosteric NMDA receptor modulators (CNS disorders), SAGE SNAPSHOT

Drug Name	allosteric NMDA receptor modulators (CNS disorders), SAGE
Key Synonyms	
Originator Company	SAGE Therapeutics Inc
Active Companies	SAGE Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Psychiatric disorder;Central nervous system disease
Target-based Actions	NMDA receptor modulator
Other Actions	Neuroprotectant
Technologies	Small molecule therapeutic
Last Change Date	24-Feb-2015

allosteric NMDA receptor modulators (CNS disorders), SAGE DEVELOPMENT PROFILE

SUMMARY

SAGE Therapeutics is investigating a program of positive and negative allosteric modulators of NMDA receptors and class of glutamate receptors, including SGE-301, for the potential treatment of CNS disorders and also investigating other NMDA receptor modulator, for the treatment of psychiatric disorder including schizophrenia, autism, depression and pain, and CNS disorders including epilepsy, Alzheimer's disease, Parkinson's disease,,,. In August 2013, the program was listed as being in preclinical development ; in November 2014, preclinical data were presented. In April 2012, the company expected to initiate clinical trials in its lead program within two years. In March 2014, the company was seeking to outlicense its programs.

allosteric NMDA receptor modulators (CNS disorders), SAGE DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
SAGE Therapeutics Inc	Central nervous system disease	US	Discovery	18-Oct-2011
SAGE Therapeutics Inc	Psychiatric disorder	US	Discovery	17-Jan-2014

[Return to Table of Contents](#)


allosteric NMDA receptor modulators (CNS disorders), SAGE DRUG NAMES

Names	Type
SGE-301	Research Code
allosteric NMDA receptor modulators (CNS disorders), SAGE	
allosteric glutamate receptor modulators (CNS disorders), SAGE	

allosteric NMDA receptor modulators (CNS disorders), SAGE DEALS AND PATENTS

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
SAGE Therapeutics Inc	1	0	1
Third Rock Ventures	0	1	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	1

[Return to Table of Contents](#)

allosteric modulators (Captisol, CNS disorders), Ligand/ SAGE

allosteric modulators (Captisol, CNS disorders), Ligand/ SAGE SNAPSHOT

Drug Name	allosteric modulators (Captisol, CNS disorders), Ligand/ SAGE
Key Synonyms	
Originator Company	Ligand Pharmaceuticals Inc
Active Companies	SAGE Therapeutics Inc;Ligand Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Central nervous system disease
Target-based Actions	
Other Actions	CNS modulator;Unspecified drug target
Technologies	Small molecule therapeutic
Last Change Date	25-Mar-2015

allosteric modulators (Captisol, CNS disorders), Ligand/ SAGE DEVELOPMENT PROFILE

SUMMARY

Ligand Pharmaceuticals and licensee SAGE Therapeutic are investigating allosteric receptor modulators that use Ligand's Captisol technology, for the potential treatment of CNS diseases. In October 2011, preclinical development was ongoing ; in March 2015, this was still the case. In April 2012, SAGE expected to initiate clinical trials in its lead program within two years.

allosteric modulators (Captisol, CNS disorders), Ligand/ SAGE DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Ligand Pharmaceuticals Inc	Central nervous system disease	US	Discovery	13-Oct-2011
SAGE Therapeutics Inc	Central nervous system disease	US	Discovery	13-Oct-2011


allosteric modulators (Captisol, CNS disorders), Ligand/ SAGE DRUG NAMES

Names	Type
allosteric modulators (Captisol, CNS disorders), Ligand/ SAGE	

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
SAGE Therapeutics Inc	0	0	1	0	1
Ligand Pharmaceuticals Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Technology - Other Proprietary	1	0	1

[Return to Table of Contents](#)

SAGE-217

SAGE-217 SNAPSHOT

Drug Name	SAGE-217
Key Synonyms	
Originator Company	SAGE Therapeutics Inc
Active Companies	SAGE Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Rett syndrome;Epilepsy
Target-based Actions	GABA A receptor modulator
Other Actions	Neuroprotectant;Anticonvulsant agent
Technologies	Oral formulation;Small molecule therapeutic;Steroid
Last Change Date	15-May-2015

SAGE-217 DEVELOPMENT PROFILE

SUMMARY

SAGE is investigating SAGE-217, a second generation oral neuroactive steroid which acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes, for the potential treatment of epilepsy disorders including Rett syndrome, Dravet syndrome and status epilepticus. In September 2014, preclinical data were presented. In November 2014, the company was planning to file an IND in late 2015. In May 2015, the company planned to initiate a phase I trial by the end of 2015.

SAGE-217 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
SAGE Therapeutics Inc	Epilepsy	US	Discovery	02-Sep-2014
SAGE Therapeutics Inc	Rett syndrome	US	Discovery	02-Sep-2014

SAGE-217 DRUG NAMES

Names	Type
SAGE-217	Research Code
GABA A allosteric modulator (oral/steroid, epilepsy disorders), SAGE therapeutics	

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

